Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 68.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,741 shares of the company's stock after purchasing an additional 7,626 shares during the period. AbbVie comprises about 1.8% of Carolina Wealth Advisors LLC's portfolio, making the stock its 12th largest position. Carolina Wealth Advisors LLC's holdings in AbbVie were worth $4,716,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of AbbVie during the 4th quarter worth approximately $5,865,055,000. Wellington Management Group LLP increased its position in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Capital World Investors lifted its holdings in AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares during the period. Cardano Risk Management B.V. boosted its position in AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock worth $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Cantor Fitzgerald lifted their price objective on shares of AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $298.00 target price on shares of AbbVie in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.70.

AbbVie Price Performance

Shares of ABBV opened at $247.86 on Tuesday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The stock's fifty day moving average price is $242.67 and its two-hundred day moving average price is $225.28. The firm has a market cap of $437.92 billion, a PE ratio of 70.02, a PEG ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 EPS. The firm's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
• Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source